ArticleAmerican journal of translational research2025
Hematological parameters as predictors of immune-related adverse events: risk factor analysis in non-small cell lung cancer patients undergoing immunotherapy.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitors.Journal of thoracic disease · 2026Article
- Determinants of severity in immune checkpoint inhibitor-related pneumonitis: clinical, radiologic, and laboratory insights from real-life clinical data.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the predictive value of hematological biomarkers in assessing the risk of immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy and to identify potential risk factors for personalized treatment optimization.
methodsClinical data of 274 NSCLC patients who received immunotherapy between April 2018 and January 2021 were retrospectively analyzed. Patients were divided into irAEs and non-irAEs groups based on the occurrence of irAEs. Peripheral blood indices within one week before treatment initiation were assessed and compared, including absolute neutrophil count (ANC), lymphocyte count (LYM), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), albumin-to-alkaline phosphatase ratio (AAPR), and albumin-to-fibrinogen ratio (AFR). Kaplan-Meier analysis compared overall survival (OS) and progression-free survival (PFS), while logistic regression identified independent risk factors for irAEs. Receiver operating characteristic (ROC) curve analysis evaluated predictive performance.
resultsAmong the 274 patients, 116 (42.2%) developed irAEs. Compared to the non-irAEs group, the irAEs group exhibited significantly higher ANC, NLR, PLR, and SII, along with lower LYM, AAPR, and AFR as well as lower OS and PFS rates (all P < 0.05). Logistic regression showed that all hematological indicators were independent risk factors for irAEs (P < 0.05). ROC analysis showed an AUC of 0.722 for NLR and 0.829 for the combined model.
conclusionPretreatment assessment of ANC, LYM, NLR, PLR, SII, AAPR, and AFR provides valuable predictive utility for irAEs risk in NSCLC patients undergoing immunotherapy. Integrating these biomarkers into clinical practice may enhance risk stratification and guide personalized treatment strategies to improve safety and therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.